If you ask any cannabis user about cannabidiol (CBD), they will immediately be able to recognize the compound, since it has been touted by the medical community so much. But what if you were to ask about other cannabinoids? What about cannabichromene (CBC)? Would they know? Probably not. Not a lot of people know about the positive effects of this cannabinoid.
Cannabichromene (CBC) is one of the 113 cannabinoids found in the cannabis plant and it bears structural similarity to the other natural cannabinoids, including tetrahydrocannabinol (THC) and CBD. It is a rare, non-psychoactive cannabinoid, like CBD.
Scientists have recently discovered that CBC may have anti-inflammatory, anti-viral, and antifungal effects, along with pain relief and anti-depressive effects. They have discovered that CBC may even react with other receptors in the body aside from the infamous CB1 and CB2 receptors that everyone knows.
CBC has also been shown to improve the pain-relieving effects of THC and it has shown to have sedative effects, promoting relaxation in mice while not exposing them to the “high” generally felt by THC.
Another interesting fact about CBC is that it has demonstrated possible neurogenesis, meaning it can grow growth new nervous tissue and is extremely significant for neurodegenerative diseases like fibromyalgia and multiple sclerosis.
The medical community is on the lookout for this compound and is touting it as the next CBD in cannabis therapy. They are quick to point out, however, that the research is still minimal where CBC is concerned and that patients should be aware of that before discussing it with their physicians.
While we still have some time before actually calling CBC the new CBD, this certainly isn’t the last that we will hear of this compound. It is definitely something the scientific community should be proud and eager to learn about, as it can provide a vast amount of relief to many patients.